| FBCIX | RAZAX | FBCIX / RAZAX | |
| Total Expense Ratio | 0.36 | 1.14 | 32% |
| Annual Report Gross Expense Ratio | 0.36 | 1.32 | 27% |
| Fund Existence | 5 years | 8 years | - |
| Gain YTD | 16.926 | 14.047 | 120% |
| Front Load | N/A | 6% | - |
| Min. Initial Investment | 250 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 119B | 577M | 20,624% |
| Annual Yield % from dividends | 3.12 | 3.16 | 99% |
| Returns for 1 year | 13.32 | 12.54 | 106% |
| Returns for 3 years | 39.28 | 41.58 | 94% |
| Returns for 5 years | 53.07 | 25.83 | 205% |
| Returns for 10 years | N/A | N/A | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JPIE | 46.27 | 0.01 | +0.02% |
| JPMorgan Income ETF | |||
| CPNS | 26.98 | N/A | +0.01% |
| Calamos Nasdaq-100 Str Alt Prt ETF-Sep | |||
| PFO | 9.51 | N/A | N/A |
| Flaherty & Crumrine Preferred and Income Opportunity Fund | |||
| JUNT | 35.48 | -0.08 | -0.22% |
| AllianzIM U.S. Large Cp Buffer10 Jun ETF | |||
| HQL | 17.18 | -0.07 | -0.41% |
| abrdn Life Sciences Investors | |||